Cite
HARVARD Citation
Wick, W. et al. (n.d.). 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab. Immuno-oncology technology. p. . [Online].